

Title: Clinical Issues™ in Psoriasis Debates and Discussions About Pustular Disease Subtypes

Dates: 5/14/2019 – 5/14/2020

Locations: <https://www.exchangecme.com/PSO2019>

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Describe the genetic and pathophysiologic mechanisms that contribute to the development of pustular psoriasis including factors that have informed the development of new therapies
- Comprehensively assess patients with suspected pustular psoriasis based on clinical manifestations, diagnostic criteria, and disease severity
- Describe the mechanistic rationales and clinical evidence for current and emerging biologic therapies for the treatment of generalized pustular psoriasis and palmoplantar pustulosis
- Individualize therapeutic regimens for pustular psoriasis, with a focus on generalized disease subtypes and palmoplantar pustulosis

Target Audience

The educational design of this activity addresses the needs of dermatologists, clinical immunologists, and other clinicians involved in the treatment and management of patients with pustular psoriasis.

Program Overview

Pustular psoriasis is a relatively rare form of psoriasis and has historically been classified into generalized and localized forms of the disease.¹ Generalized pustular psoriasis is characterized by widespread sterile pustules on erythematous skin, recurrent fever, and systemic flushing and malaise.^{1,2} Palmoplantar pustulosis, a localized form, is characterized by erythema, pruritis, burning, and pain on the palms and soles. Recent evidence suggests that IL36RN mutations are the most common genetic aberration linked to pustular psoriasis, with the allelic frequency distinguishing generalized pustular psoriasis and palmoplantar pustulosis; the former shows a 4 to 1 increase versus the latter.³ Whether pustular psoriasis presents as localized or generalized, patients are subject to significant health risks and poor quality of life outcomes due to both skin and systemic manifestations. Patients may be subject to delays in diagnosis, in part because the disease states are relatively rare and there are little solid epidemiologic data.⁴ Dermatologists are faced with limited guidance on selecting therapies for patients with any of the pustular psoriasis subtypes.¹ Biologic agents for pustular psoriasis and palmoplantar pustulosis are being examined in clinical trials. These include some biologics approved for psoriasis as well as agents with novel therapeutic targets, such as an anti-interleukin (IL)-36 receptor antibody.⁵ This Clinical Issues enduring activity will use both lecture and faculty discussion among leading dermatology experts to explore many of these issues, with an emphasis on evolving diagnostic and management strategies for generalized pustular psoriasis and palmoplantar pustulosis.

Faculty

Jeffrey J. Crowley, MD
Bakersfield Dermatology and Skin Cancer Medical Center
Bakersfield, California

Abby S. Van Voorhees, MD
Chair, Department of Dermatology
Eastern Virginia Medical School
Norfolk, Virginia

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and Integritas. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement

Clinical and Patient Educators Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

CPEA requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim.